CompletedNCT04591626AWARD-CHN3Updated May 24, 2023Results posted

A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes

A Phase 3 interventional study of Dulaglutide and Placebo in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 27 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-24.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Phase: Phase 3
Study type: Interventional
Enrollment: 291
Allocation: Randomized
Ages: 18 Years and older
Sex: All

Study summary

The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.

Conditions studied

Type 2 Diabetes Mellitus

Browse trials for

Keywords

T2DM
LY2189265

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 291 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.

Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

have type 2 diabetes
are men or nonpregnant women aged ≥18 years at screening
have been treated with basal insulin glargine once daily and metformin and/or acarbose for at least 3 months prior to screening
doses of once daily insulin glargine and OAMs must be stable during the 3-month period prior to screening. Insulin glargine dose is considered stable when all doses during this period are within the range defined by ±20% of the most commonly used insulin glargine dose during this same period. Doses of metformin and/or acarbose are considered stable when doses are unchanged during the same period, and the doses should be in the inclusive range of the half maximum to maximum approved daily dose per the locally-approved label
have an HbA1c value ≥7.0% and ≤11.0% as assessed by the central laboratory at screening
require further insulin glargine dose increase at baseline per the TTT algorithm based on the SMBG data (FBG ≥5.6mmol/L) collected during the prior week
have stable weight (±5%) ≥3 months prior to screening
have body mass index (BMI) between ≥19.0 and ≤35.0 kg/m2 at screening

Exclusion criteria

Exclusion Criteria:

have type 1 diabetes (T1D)
have a history of ≥1 episode of ketoacidosis or hyperosmolar state/coma
have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening
have had any of the following CV conditions within the 2 months prior to screening: acute myocardial infarction (MI), New York Heart Association (NYHA) Class III or Class IV heart failure, or cerebrovascular accident (stroke)
have a known clinically significant gastric emptying abnormality (eg, severe diabetic gastroparesis or gastric outlet obstruction) or have undergone or plan to have a gastric bypass (bariatric) surgery or restrictive bariatric surgery (eg, Lap-Band®) during the course of the study, or chronically take drugs that directly affect gastrointestinal (GI) motility
have a history of chronic pancreatitis or acute idiopathic pancreatitis, or were diagnosed with any type of acute pancreatitis within the 3 months prior to screening
for participants on metformin or metformin and acarbose, have renal disease or renal dysfunction (eGFR [CKD-EPI] \<45 mL/min/1.73 m2), as determined by the central laboratory; for participants on acarbose, have renal disease or renal dysfunction (eGFR [CKD-EPI] \<25 mL/min/1.73 m2), as determined by the central laboratory
have any self or family history of type 2A or type 2B multiple endocrine neoplasia (MEN 2A or 2B) syndrome in the absence of known C-cell hyperplasia (the only exception for this exclusion will be for participants whose family members with MEN 2A or 2B syndrome have a known RET mutation and the potential participant for the study is negative for the RET mutation)
have any self or family history of medullary C-cell hyperplasia, focal hyperplasia, or carcinoma (including sporadic, familial, or part of MEN 2A or 2B syndrome)
have serum calcitonin ≥20 pg/mL at screening, as determined by the central laboratory
have any hematologic condition that may interfere with HbA1c measurement (eg, hemolytic anemias, sickle-cell disease)
have been treated with any other antihyperglycemia regimen, other than basal insulin glargine once daily and metformin and/or acarbose, within the 3 months prior to screening or between screening and baseline

Study design

Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Double (Participant, Investigator)
Enrollment: 291 participants (actual)

Study arms

Experimental
1.5 Milligrams (mg) Dulaglutide
Participants received 1.5 mg Dulaglutide administered once weekly (QW) subcutaneously (SC) as add-on to titrated treat-to-target (TTT) dose of Insulin Glargine given SC, along with metformin and/or acarbose.
Drug: Dulaglutide · Drug: Insulin Glargine
Placebo comparator
Placebo
Participants received placebo administered QW SC as add-on to titrated TTT dose of insulin glargine given SC, along with metformin and/or acarbose.
Drug: Placebo · Drug: Insulin Glargine

Interventions

DrugDulaglutide
Administered SC
Also known as: LY2189265
DrugPlacebo
Administered SC
DrugInsulin Glargine
Administered SC

What researchers measure

Primary outcomes

Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Oral Antihyperglycemic Medications (OAM) use + Treatment + Visit + Treatment\*Visit (Type III sum of squares) as variables.
Time frame: Baseline, Week 28

Secondary outcomes

Percentage of Participants Achieving HbA1c <7.0%
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Odds Ratio (OR) was determined using longitudinal logistic regression model with Baseline HbA1c value + OAM use + Treatment + Visit + Treatment\*Visit as variables.
Time frame: Week 28
Change From Baseline in Body Weight
Change from baseline in body weight was reported here. LS mean was determined by MMRM model with Baseline + Baseline HbA1c strata (\<8.5%, \>=8.5%) + OAM use + Treatment + Visit + Treatment\*Visit (Type III sum of squares) as variables.
Time frame: Baseline, Week 28
Change From Baseline in Fasting Serum Glucose (FSG)
Change from baseline in FSG was reported here. LS mean was determined using MMRM model with Baseline + Baseline HbA1c strata (\<8.5%, \>=8.5%) + OAM use + Treatment + Visit + Treatment\*Visit (Type III sum of squares) as variables.
Time frame: Baseline, Week 28
Percentage of Participants Achieving HbA1c <7.0% With no Weight Gain (<0.1 kg) and Without Documented Symptomatic Hypoglycemia (Blood Glucose <3.0 mmol/L)
Percentage of Participants Achieving HbA1c \<7.0% With no Weight Gain (\<0.1 kg) and Without Documented Symptomatic Hypoglycemia (Blood Glucose \<3.0 mmol/L) was reported here.
Time frame: Week 28
Percentage of Participants Achieving HbA1c <7.0% Without Documented Symptomatic Hypoglycemia (Blood Glucose <3.0 mmol/L)
Percentage of Participants Achieving HbA1c \<7.0% Without Documented Symptomatic Hypoglycemia (Blood Glucose \<3.0 mmol/L) was reported here.
Time frame: Week 28
Percentage of Participants Achieving HbA1c <7.0% Without Weight Gain (<0.1 kg)
Percentage of Participants Achieving HbA1c \<7.0% Without Weight Gain (\<0.1 kg) was reported here.
Time frame: Week 28
Change From Baseline in Blood Glucose From Daily Self-Monitored Blood Glucose (SMBG) Profile
The SMBG data was collected at the following 7 time points: Pre morning meal BG, 2-hour postprandial measurement for morning meal BG, Pre midday meal BG, 2-hour postprandial measurement for midday meal BG, Pre evening meal BG, 2-hour postprandial measurement for evening meals BG, and Bedtime BG. LS mean was determined using MMRM model with Baseline + OAM (metformin and/or acarbose) usage + HbA1c Group at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 28
Change From Baseline in Daily Mean Insulin Glargine Doses
LS mean was determined using MMRM model with Baseline + Baseline HbA1c strata (\<8.5%, \>=8.5%) + OAM use + Treatment + Visit + Treatment\*Visit (Type III sum of squares) as variables.
Time frame: Baseline, Week 28

Results

Posted May 24, 2023

Participant flow

Participant flow — Overall Study
Milestone	1.5 Milligrams (mg) Dulaglutide	Placebo
Started	144	147
Received at least one dose of study drug	144	147
Completed	134	142
Not completed	10	5
Withdrew: Adverse event	4	0
Withdrew: Withdrawal by subject	5	3
Withdrew: Physician decision	0	1
Withdrew: Death	0	1
Withdrew: Non-compliance with study drug	1	0

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Oral Antihyperglycemic Medications (OAM) use + Treatment + Visit + Treatment\*Visit (Type III sum of squares) as variables.

Time frame:: Baseline, Week 28
Reported as:: Least squares mean · Percentage of HbA1c

Change From Baseline in Hemoglobin A1c (HbA1c)
Percentage of HbA1c	1.5 mg Dulaglutide	Placebo
Change From Baseline in Hemoglobin A1c (HbA1c)	-2.03 ± 0.076	-1.08 ± 0.073

Statistical analysis

1.5 mg Dulaglutide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.95 · 95% CI -1.14 to -0.77

SecondaryPercentage of Participants Achieving HbA1c <7.0%

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Odds Ratio (OR) was determined using longitudinal logistic regression model with Baseline HbA1c value + OAM use + Treatment + Visit + Treatment\*Visit as variables.

Time frame:: Week 28
Reported as:: Number · Percentage of participants

Percentage of Participants Achieving HbA1c <7.0%
Percentage of participants	1.5 mg Dulaglutide	Placebo
Percentage of Participants Achieving HbA1c <7.0%	75.9	33.8

Statistical analysis

1.5 mg Dulaglutide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 10.91 · 95% CI 5.35 to 22.28

SecondaryChange From Baseline in Body Weight

Change from baseline in body weight was reported here. LS mean was determined by MMRM model with Baseline + Baseline HbA1c strata (\<8.5%, \>=8.5%) + OAM use + Treatment + Visit + Treatment\*Visit (Type III sum of squares) as variables.

Time frame:: Baseline, Week 28
Reported as:: Least squares mean · kilogram (kg)

Change From Baseline in Body Weight
kilogram (kg)	1.5 mg Dulaglutide	Placebo
Change From Baseline in Body Weight	-0.76 ± 0.224	0.42 ± 0.217

Statistical analysis

1.5 mg Dulaglutide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.18 · 95% CI -1.77 to -0.60

SecondaryChange From Baseline in Fasting Serum Glucose (FSG)

Change from baseline in FSG was reported here. LS mean was determined using MMRM model with Baseline + Baseline HbA1c strata (\<8.5%, \>=8.5%) + OAM use + Treatment + Visit + Treatment\*Visit (Type III sum of squares) as variables.

Time frame:: Baseline, Week 28
Reported as:: Least squares mean · milligrams per deciliter (mg/dL)

Change From Baseline in Fasting Serum Glucose (FSG)
milligrams per deciliter (mg/dL)	1.5 mg Dulaglutide	Placebo
Change From Baseline in Fasting Serum Glucose (FSG)	-58.47 ± 2.339	-43.64 ± 2.269

Statistical analysis

1.5 mg Dulaglutide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -14.82 · 95% CI -20.57 to -9.08

SecondaryPercentage of Participants Achieving HbA1c <7.0% With no Weight Gain (<0.1 kg) and Without Documented Symptomatic Hypoglycemia (Blood Glucose <3.0 mmol/L)

Percentage of Participants Achieving HbA1c \<7.0% With no Weight Gain (\<0.1 kg) and Without Documented Symptomatic Hypoglycemia (Blood Glucose \<3.0 mmol/L) was reported here.

Time frame:: Week 28
Reported as:: Number · Percentage of participants

Percentage of Participants Achieving HbA1c <7.0% With no Weight Gain (<0.1 kg) and Without Documented Symptomatic Hypoglycemia (Blood Glucose <3.0 mmol/L)
Percentage of participants	1.5 mg Dulaglutide	Placebo
Percentage of Participants Achieving HbA1c <7.0% With no Weight Gain (<0.1 kg) and Without Documented Symptomatic Hypoglycemia (Blood Glucose <3.0 mmol/L)	51.8	21.1

Statistical analysis

1.5 mg Dulaglutide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.58 · 95% CI 2.64 to 7.95OR was determined using Logistic Regression model with Baseline HbA1c value + OAM use + Treatment as variables.

SecondaryPercentage of Participants Achieving HbA1c <7.0% Without Documented Symptomatic Hypoglycemia (Blood Glucose <3.0 mmol/L)

Percentage of Participants Achieving HbA1c \<7.0% Without Documented Symptomatic Hypoglycemia (Blood Glucose \<3.0 mmol/L) was reported here.

Time frame:: Week 28
Reported as:: Number · Percentage of participants

Percentage of Participants Achieving HbA1c <7.0% Without Documented Symptomatic Hypoglycemia (Blood Glucose <3.0 mmol/L)
Percentage of participants	1.5 mg Dulaglutide	Placebo
Percentage of Participants Achieving HbA1c <7.0% Without Documented Symptomatic Hypoglycemia (Blood Glucose <3.0 mmol/L)	74.8	33.3

Statistical analysis

1.5 mg Dulaglutide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 7.59 · 95% CI 4.27 to 13.48OR was determined using logistic regression model: Variable = Baseline HbA1c value + OAM use + Treatment as variables.

SecondaryPercentage of Participants Achieving HbA1c <7.0% Without Weight Gain (<0.1 kg)

Percentage of Participants Achieving HbA1c \<7.0% Without Weight Gain (\<0.1 kg) was reported here.

Time frame:: Week 28
Reported as:: Number · Percentage of participants

Percentage of Participants Achieving HbA1c <7.0% Without Weight Gain (<0.1 kg)
Percentage of participants	1.5 mg Dulaglutide	Placebo
Percentage of Participants Achieving HbA1c <7.0% Without Weight Gain (<0.1 kg)	51.8	21.1

Statistical analysis

1.5 mg Dulaglutide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.58 · 95% CI 2.64 to 7.95OR was determined using logistic regression model with Baseline HbA1c value + OAM use + Treatment as variables.

SecondaryChange From Baseline in Blood Glucose From Daily Self-Monitored Blood Glucose (SMBG) Profile

The SMBG data was collected at the following 7 time points: Pre morning meal BG, 2-hour postprandial measurement for morning meal BG, Pre midday meal BG, 2-hour postprandial measurement for midday meal BG, Pre evening meal BG, 2-hour postprandial measurement for evening meals BG, and Bedtime BG. LS mean was determined using MMRM model with Baseline + OAM (metformin and/or acarbose) usage + HbA1c Group at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:: Baseline, Week 28
Reported as:: Least squares mean · milligrams per deciliter (mg/dL)

Change From Baseline in Blood Glucose From Daily Self-Monitored Blood Glucose (SMBG) Profile
milligrams per deciliter (mg/dL)	1.5 mg Dulaglutide	Placebo
Change From Baseline in Blood Glucose From Daily Self-Monitored Blood Glucose (SMBG) Profile	-64.0 ± 2.42	-37.7 ± 2.36

Statistical analysis

1.5 mg Dulaglutide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -26.3 · 95% CI -33.0 to -19.6

SecondaryChange From Baseline in Daily Mean Insulin Glargine Doses

LS mean was determined using MMRM model with Baseline + Baseline HbA1c strata (\<8.5%, \>=8.5%) + OAM use + Treatment + Visit + Treatment\*Visit (Type III sum of squares) as variables.

Time frame:: Baseline, Week 28
Reported as:: Least squares mean · International Units per day(IU/day)

Change From Baseline in Daily Mean Insulin Glargine Doses
International Units per day(IU/day)	1.5 mg Dulaglutide	Placebo
Change From Baseline in Daily Mean Insulin Glargine Doses	10.0 ± 1.045	14.0 ± 1.015

Statistical analysis

1.5 mg Dulaglutide vs Placebo · Mixed Models Analysis · p = 0.006 · Ls mean difference: -4.0 · 95% CI -6.86 to -1.14

Adverse events

Collected over Baseline Through End of Safety Follow-Up (Up To 32 Weeks). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
Group	Deaths	Serious	Other
1.5 mg Dulaglutide	0/144 (0%)	8/144 (5.6%)	113/144 (78.5%)
Placebo	1/147 (0.7%)	12/147 (8.2%)	99/147 (67.3%)

Most frequent serious events

Showing 10 of 24

Most frequent serious events
Event	1.5 mg Dulaglutide	Placebo
Chronic gastritisGastrointestinal disorders	0/144	2/147
Abdominal adhesionsGastrointestinal disorders	1/144	0/147
Duodenal ulcer haemorrhageGastrointestinal disorders	1/144	0/147
Large intestine polypGastrointestinal disorders	1/144	1/147
Cholecystitis acuteHepatobiliary disorders	1/144	0/147
CholelithiasisHepatobiliary disorders	1/144	0/147
AppendicitisInfections and infestations	1/144	0/147
Diabetes mellitus inadequate controlMetabolism and nutrition disorders	1/144	0/147
OsteoarthritisMusculoskeletal and connective tissue disorders	1/144	0/147
Cerebral infarctionNervous system disorders	1/144	0/147

Most frequent other events

Showing 10 of 83

Most frequent other events
Event	1.5 mg Dulaglutide	Placebo
Decreased appetiteMetabolism and nutrition disorders	32/144	6/147
Diabetic nephropathyRenal and urinary disorders	20/144	22/147
DiarrhoeaGastrointestinal disorders	19/144	12/147
NauseaGastrointestinal disorders	15/144	8/147
VomitingGastrointestinal disorders	13/144	2/147
Abdominal distensionGastrointestinal disorders	11/144	2/147
Upper respiratory tract infectionInfections and infestations	11/144	10/147
HyperglycaemiaMetabolism and nutrition disorders	4/144	11/147
HyperlipidaemiaMetabolism and nutrition disorders	9/144	7/147
DyspepsiaGastrointestinal disorders	8/144	1/147

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)	1.5 mg Dulaglutide	Placebo	Total
Mean	57.80 ± 9.33	58.30 ± 9.48	58.10 ± 9.39

Sex: Female, Male
Sex: Female, Male(Participants)	1.5 mg Dulaglutide	Placebo	Total
Female	52	57	109
Male	92	90	182

Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)	1.5 mg Dulaglutide	Placebo	Total
Hispanic or Latino	0	0	0
Not Hispanic or Latino	0	0	0
Unknown or Not Reported	144	147	291

Race (NIH/OMB)
Race (NIH/OMB)(Participants)	1.5 mg Dulaglutide	Placebo	Total
American Indian or Alaska Native	0	0	0
Asian	144	147	291
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	0	0	0
More than one race	0	0	0
Unknown or Not Reported	0	0	0

Region of Enrollment
Region of Enrollment(Participants)	1.5 mg Dulaglutide	Placebo	Total
China	144	147	291

Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(Percentage of HbA1c)	1.5 mg Dulaglutide	Placebo	Total
Mean	8.60 ± 1.00	8.58 ± 0.97	8.59 ± 0.98

Study locations

27 sites

The Second People's Hospital of Hefei
Hefei, Anhui 230011, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong 510120, China
First Affiliated Hospital of the Harbin Medical University
Harbin, Heilongjiang 150001, China
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang 150001, China
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang Shi, Henan 471003, China
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou Shi, Henan 450014, China
Changzhou No.2 People's Hospital
Changzhou, Jiangsu 213003, China
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu 210000, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu 210011, China
The First Hospital of Nanjing
Nanjing, Jiangsu 210012, China
Nanjing Medical University - Nanjing Jiangning Hospital
Nanjing, Jiangsu 211100, China
No. 2 Affiliated Hospital of Suzhou University
Suzhou Shi, Jiangsu 215004, China
Wuxi People's Hospital
Wuxi, Jiangsu 214023, China
The Third Hospital of Nanchang
Nanchang, Jiangxi 330009, China
Pingxiang People's Hospital
Pingxiang, Jiangxi 337000, China
The First Hospital of Jilin University
Changchun, Jilin 130021, China
Dalian Municipal Central Hospital Affiliated of Dalian Medical University
Dalian, Liaoning 116033, China
Jinan Central Hospital
Jinan, Shandong 250013, China
Shanghai Putuo District Center Hospital
Shanghai, Shanghai 200062, China
The First Affiliated Hospital of Xi'an Medical University
XI 'an, Shanxi 710077, China
West China Hospital Sichuan University
Chengdu, Sichuan 610041, China
Tianjin Medical University General Hospital
Tianjin, Tianjin 300052, China
The Affiliated Jiangyin Hospital of Southeast University Medical College
Wuxi Shi, Wuxi Shi 214400, China
The First People's Hospital of Yunnan Province
Kunming, Yunnan 650034, China
Chongqing General Hospital
Chongqing, Yuzhong District 400014, China
Zhejiang Hospital
Hangzhou, Zhejiang 310013, China
Beijing Pinggu District Hospital
Beijing, 101200, China

References and documents

Study documents

Study protocol · Jul 30, 2020
Statistical analysis plan · Jun 29, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Sap, Csr

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on May 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT04591626
Lead sponsor: Eli Lilly and Company
Responsible party: Sponsor
First posted: Oct 19, 2020
Start date: Dec 7, 2020
Primary completion: Apr 28, 2022
Completion: Apr 28, 2022
Results posted: May 24, 2023
Last update: May 24, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

study director · Eli Lilly and Company

Oversight

Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Diabetes Mellitus→

Other studies from this sponsor

Eli Lilly and Company

Start the discussion

A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes

Study summary

Conditions studied

Browse trials for

Keywords

In context

Diabetes Mellitus

Lead sponsor

Who can participate

✓Inclusion criteria

✕Exclusion criteria

Study design

Study arms

Interventions

What researchers measure

Primary outcomes

Secondary outcomes

Results

Participant flow

Outcome measures

Adverse events

Baseline characteristics

Study locations

References and documents

Study documents

Individual participant data

Updates

Registry details

Key details

Study contacts

Oversight

Not currently enrolling

Follow this study

Discussion

Other studies in this condition

Other studies from this sponsor

Inclusion criteria

Exclusion criteria